An experimental treatment happens to be the solution to delay Alzheimer's symptoms in some people. These people are the ones who are genetically destined to get the disease in their 40s or 50s. These new findings form ongoing research has now been caught up in Trump administration funding delas. The early results of the study has been published on Wednesday and the participants too are worried that politics could cut their access to a possible lifeline.

One of the participants had said, "It is still a study but it has given me an extension to my life that I never banked on having." The participant is named Jake Henrichs, form New York City, who is 50 years old. He is one of them to be treated in that study for more than a decade now and has remained symptom-free despite inheriting an Alzheimer's-causing gene that had killed his father and brother around the same age.

Slowing Down The Symptoms

Two drugs which can modestly slow down early-stage Alzheimer's are sold in the United States. These drugs clear the brain of one of its hallmarks, a sticky gunk-like part called the amyloid. However, there have not been any hints that removing amyloid far earlier, way many years before the first symptoms appear, may postpone the disease.

How Was The Research Conducted?

The research is led by Washington University in St Louis, which involved families that passed down rare gene mutation as participants. This meant it was almost guaranteed that they will develop symptoms at the same age their affected relatives did.

The new findings is based on a subset of 22 participants who received amyloid-removing drugs the longest, on average eight years. Long-term amyloid removal cut in half their risk of symptom onset. The study is published in the journal Lancet Neurology.

Washington University's Dr Randall Bateman, who directs the Dominantly Inherited Alzheimer's Network of studies involving families with these rare genes says, "What we want to determine over the next five years is how strong is the protection. Will they ever get the symptoms of Alzheimer’s disease if we keep treating them?”

The researchers before though did not know what exactly caused Alzheimer's which affects nearly 7 million Americans, most of them in their later life. However, it is clear that these silent changes occur in the brain at least two decades before the first symptom shows up. The big contributor. At some point amyloid buildup can trigger a protein named tau that then starts to kill neurons, which can lead to cognitive decline.

Researchers are now thus studying the Tau-fighting drugs and are looking into other factors, like inflammation, brain's immune cells and certain virus.

The National Institute of Health (NIH) has expanded its focus as researchers have found more reasons for Alzheimer's. In 2013, the NIH's National Institute on Aging funded 14 trials of possible Alzheimer's drugs over a third targeting amyloid. By last fall, there were 68 drugs and 18% of them target amyloid. However, there are scientists too who think that amyloid is not everything and their is way more in the brain tissue, immune cells, and more which can be studied.

The World Health Organization (WHO) has warned that West Nile virus infections are increasing across parts of Europe, with hotter temperatures, longer summers, and changing weather patterns creating ideal conditions for mosquito-borne disease transmission.

The warning comes as Europe grapples with intense heatwaves and widespread wildfires, which experts say are contributing to the spread of disease-carrying mosquitoes.

Cases Rising Across Southern Europe

Greece has recorded the sharpest recent increase, with 21 confirmed human cases as of July 22, including 14 reported in the previous week alone.

Of these, 20 patients developed neuroinvasive disease, such as encephalitis or meningitis, and 13 remain hospitalized.

Italy has reported the widest geographic spread, with 21 confirmed cases across 17 different areas as of July 15. Locally acquired infections have also been reported in North Macedonia (2 cases), Romania (2), and Spain (2).

The WHO noted that while the risk remains low for most people, it may turn deadly for some.

"West Nile virus is not a new threat, but the conditions driving its spread are changing rapidly," said Dr. Hans Henri P. Kluge, WHO Regional Director for Europe.

“Most infections are mild, but roughly 1 in 150 people who contract the virus will develop a severe infection affecting the central nervous system, which can be life-threatening,” he added.

Kluge added that warmer temperatures and longer summers are giving mosquitoes more time and a wider geographic range to transmit the virus.

What Is West Nile Virus?

West Nile virus is spread primarily through the bite of an infected mosquito. Mosquitoes become infected after feeding on infected birds and can then transmit the virus to humans and other animals.

In Europe, infections typically occur during the mosquito season—from late spring through autumn—with transmission peaking between July and September.

Although rare, the virus has also been transmitted through blood transfusions, organ transplantation, pregnancy, and breastfeeding. There is no evidence of person-to-person transmission through everyday contact.

Currently, there is no licensed vaccine for humans and no specific antiviral treatment. Care focuses on relieving symptoms, while severe cases may require hospital-based supportive treatment.

Symptoms to Watch For

Around 70–80% of infected people develop no symptoms.

Those who do become ill may experience:

• Fever
• Headache
• Fatigue
• Body aches
• Nausea or vomiting
• Skin rash
• Swollen lymph nodes

In severe cases, the infection can affect the nervous system, causing:

• High fever
• Neck stiffness
• Disorientation
• Tremors
• Convulsions
• Muscle weakness
• Paralysis
• Coma

Anyone who develops symptoms after returning from an area where the virus is circulating should seek medical attention promptly. People with severe symptoms require urgent medical care.

West Nile virus infection can be confirmed through laboratory tests that detect virus-specific antibodies or viral RNA, depending on the stage of illness.

How to Protect Yourself

As there is no vaccine or specific treatment, WHO says prevention depends on avoiding mosquito bites and reducing mosquito breeding sites.

WHO recommends:

• Wear light-colored clothing that covers the arms and legs.
• Limit outdoor activities during dawn and dusk, when mosquitoes are most active.
• Apply mosquito repellents containing approved ingredients according to the manufacturer's instructions. Adults should apply repellent to young children and avoid the eyes, mouth, and hands.
• Install window and door screens to keep mosquitoes out of homes.
• Sleep in air-conditioned rooms, use fans, or sleep under mosquito nets where needed.
• Eliminate standing water from flowerpots, buckets, bird baths, clogged gutters, and other containers where mosquitoes can breed.

Israel’s military is facing an alarming mental health crisis as prolonged geopolitical conflict continues to take a psychological toll on its soldiers.

Recently, two female Israeli soldiers died by suicide within days of each other, bringing the number of active-duty military suicides this year to at least 16, according to Israeli media.

The deaths in the force have reignited concerns over whether the military personnel are receiving necessary trauma and mental health care

The latest cases involved a combat soldier from the Bardelas Battalion and an intelligence officer. Military Police have launched investigations, while the Israel Defense Forces (IDF) has acknowledged the incidents, saying that the affected units are being supported in every way.

Mental Health Crisis In Israel's Military

According to Israel’s Defence Ministry, cases of post-traumatic stress disorder (PTSD) among soldiers have increased by nearly 40% since 2023.

Of more than 22,000 personnel receiving treatment for war-related injuries, around 60% are being treated primarily for psychological trauma.

“Soldiers are grappling not only with fear for their own lives, but also with moral injury resulting from witnessing or participating in traumatic events,” clinical psychologist Ronen Sidi of Emek Medical Center told Reuters.

Also read: Many US Veterans With Suicidal Thoughts May Not Be Receiving Mental Health Treatment, Study Finds

What Is Moral Injury?

Unlike PTSD, which is often linked to fear-based traumatic experiences, moral injury refers to when patients feel they have violated deeply held moral or ethical beliefs, or witnessed events that violate those values.

Military psychologists say constant exposure to civilian casualties, loss of troops, and conflicting decisions on the battlefield can leave lasting emotional wounds that last for a long time.

Ground Reality

The two recent suicides are not isolated incidents. Earlier this year, Israeli media reported that many soldiers on active duty had taken their own lives after returning from their deployments.

Some reports also said that soldiers who were discharged are struggling with severe PTSD, depression and social isolation after leaving service. Researchers say many continue to battle mental health issues long after their duty ends.

Veterans’ organisations have increasingly called for comprehensive and effective rehabilitation services, saying that untreated trauma may surface months or even years after military service ends.

Also read: US Government Backs Psychedelic Therapies Research For Veterans With PTSD and Depression

Are Mental Health Support Systems Enough?

The Israeli Defence Ministry says it has expanded mental health services, funding and introduced alternative therapies to improve mental health recovery for soldiers who are struggling.

However, some recent reports have questioned whether those services are reaching troops quickly enough. Critics have pointed to shortages of field psychologists, cancelled mental health support days and unsuccessful recognition of warning signs.

Mental health specialists also say that stigma remains another barrier. Despite growing awareness, many soldiers hesitate to seek help because they believe that doing so could affect their careers or be viewed as a sign of weakness.

For Israel, the growing number of soldier suicides is becoming a stark reminder that the cost of war is measured not only in physical casualties, but also in the invisible wounds that reflect through mental health issues.

Uganda has officially ended the Ebola outbreak after completing the mandatory 42-day monitoring period with no new infections, even as neighboring Democratic Republic of the Congo (DRC) continues to battle its worst outbreak of the deadly disease in years.

Ugandan Health Minister Chris Baryomunsi announced the "successful completion of the mandatory 42-day monitoring period," which began after the last locally transmitted patient was discharged on June 16.

"Throughout this period, the Ministry of Health maintained intensive surveillance nationwide, and no new Ebola cases have been detected," Baryomunsi said.

Uganda Ends Outbreak After Swift Response

Earlier this month, Dr. Diana Atwine, Permanent Secretary at Uganda's Ministry of Health, said the outbreak had been successfully contained through rapid surveillance, prompt treatment, contact tracing, and close cross-border coordination.

Uganda recorded 20 confirmed Ebola cases during the outbreak. Of these, 18 patients recovered and were discharged, while two died.

Most of the infections were linked to travelers arriving from the DRC, with only a small number resulting from local transmission.

Despite the declaration, Baryomunsi urged the public to remain "vigilant" and continue following public health measures to prevent future outbreaks.

Congo Outbreak Nears Scale of Historic Epidemic

Also read: Michigan Cyclosporiasis Outbreak Nears 10,000 Cases: Is Your Lettuce Safe?

While Uganda celebrates its success, the Ebola crisis in the DRC continues to worsen. According to the Congolese Ministry of Health, the country has reported at least 3,262 cases and 1,437 deaths, bringing the outbreak close to the scale of the country's devastating 2018-2020 epidemic.

The World Health Organization (WHO) has described it as the fastest-spreading Ebola outbreak ever recorded, warning that the actual number of infections could be two to four times higher than officially reported.

UN Warns Virus Is Spreading "Like Wildfire"

United Nations humanitarian officials have described the outbreak as one of the world's most severe public health emergencies.

"The outbreak is spreading like wildfire," UN officials warned, citing armed conflict, mass displacement, and repeated attacks on healthcare facilities as major obstacles to controlling the virus.

The WHO has also warned that many newly reported infections cannot be linked to known transmission chains, suggesting the virus is spreading undetected within communities.

Contact tracing remains inadequate, while insecurity, misinformation, and community mistrust continue to undermine response efforts.

Health workers have also staged strikes in some areas over unpaid wages, further disrupting patient care and containment operations.

Attacks on health facilities, shortages of medical supplies, delayed laboratory testing, and public distrust are other factors delaying efforts to isolate patients, trace contacts, and break chains of transmission.

First Volunteer Receives Experimental Bundibugyo Vaccine

Amid the worsening outbreak, researchers have reached an important milestone in Ebola vaccine development.

The first volunteer has received an experimental vaccine targeting the Bundibugyo strain of Ebola, marking the world's first Phase I clinical trial for this virus, according to the University of Oxford.

The vaccine, ChAdOx1 BDBV, developed in collaboration with Serum Institute of India (SII), is designed specifically to protect against the Bundibugyo strain of Ebola.

It uses the same viral vector platform that powered the Oxford-AstraZeneca COVID-19 vaccine.

The vaccine uses a genetically modified chimpanzee adenovirus (ChAdOx1)—a harmless virus that normally causes the common cold in chimpanzees—as a delivery vehicle.

"We welcome the start of the phase 1 clinical trial of an investigational vaccine against Ebola Bundibugyo virus disease—an important step to assess the safety and immune responses generated by the vaccine," said WHO Director-General Tedros Adhanom Ghebreyesus on X.